

# CITATION REPORT

List of articles citing

## Simultaneous Quantification of Adalimumab and Infliximab in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry

DOI: 10.1097/ftd.00000000000000514  
Therapeutic Drug Monitoring, 2018, 40, 417-424.

Source: <https://exaly.com/paper-pdf/68927295/citation-report.pdf>  
Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
23	Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?. <i>AAPS Journal</i> , <b>2018</b> , 20, 99	3.7	15
22	Investigating the utility of minimized sample preparation and high-resolution mass spectrometry for quantification of monoclonal antibody drugs. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 159, 384-392	3.5	7
21	Six-step workflow for the quantification of therapeutic monoclonal antibodies in biological matrices with liquid chromatography mass spectrometry - A tutorial. <i>Analytica Chimica Acta</i> , <b>2019</b> , 1080, 22-34	6.6	9
20	Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2019</b> , 57, 1906-1914	5.9	11
19	A multiplex liquid chromatography tandem mass spectrometry method for the quantification of seven therapeutic monoclonal antibodies: Application for adalimumab therapeutic drug monitoring in patients with Crohn's disease. <i>Analytica Chimica Acta</i> , <b>2019</b> , 1067, 63-70	6.6	27
18	Simultaneous Quantification of Free Adalimumab and Infliximab in Human Plasma Using a Target-Based Sample Purification and Liquid Chromatography-Tandem Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 640-647	3.2	11
17	New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 722-728	3.8	3
16	Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine. <i>Annals of Laboratory Medicine</i> , <b>2020</b> , 40, 95-96	3.1	1
15	Bottom-up sample preparation for the LC-MS/MS quantification of anti-cancer monoclonal antibodies in bio matrices. <i>Bioanalysis</i> , <b>2020</b> , 12, 1405-1425	2.1	6
14	. <b>2020</b> ,		1
13	Development of a Mass Spectrometry-Based Method for Quantification of Ustekinumab in Serum Specimens. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 572-577	3.2	2
12	Therapeutic Drug Monitoring. <b>2020</b> , 479-504		1
11	Simultaneous quantification of rituximab and eculizumab in human plasma by liquid chromatography-tandem mass spectrometry and comparison with rituximab ELISA kits. <i>Clinical Biochemistry</i> , <b>2021</b> , 87, 60-66	3.5	6
10	Impact of the Opioid Epidemic on Drug Testing. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 14-24	3.2	1
9	Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 610806	5.6	6
8	The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 636420	8.4	1
7	Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring. <i>ACS Pharmacology and Translational Science</i> , <b>2020</b> , 3, 1304-1309	5.9	1

6	Direct and Precise Measurement of Bevacizumab Levels in Human Plasma Based on Controlled Methionine Oxidation and Multiple Reaction Monitoring. <i>ACS Pharmacology and Translational Science</i> , <b>2020</b> , 3, 1304-1309	5.9	4
5	Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review. <i>Pharmaceutics</i> , <b>2022</b> , 14, 1009	6.4	1
4	A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics.		
3	Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods. <i>Bioanalysis</i> ,	2.1	1
2	An Introduction to Bioanalysis of Monoclonal Antibodies. <b>2022</b> , 19-47		0
1	A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics. <b>2022</b> , 147, 4275-4284		1